Literature DB >> 15877050

Towards mutation-independent silencing of genes involved in retinal degeneration by RNA interference.

S M Cashman1, E A Binkley, R Kumar-Singh.   

Abstract

More than one hundred different mutations in the gene encoding rhodopsin are associated with a group of retinal degenerations including retinitis pigmentosa, congenital stationary night blindness and retinitis punctata albescens. Given this large heterogeneity of mutations, it would be ideal to develop mutation-independent therapies for these diseases. We describe use of RNA interference (RNAi) and specifically short hairpin RNAs (shRNAs) expressed from DNA templates to silence both normal and mutant (P23H) human rhodopsin alleles by 94.34+/-2.17 and 94.9+/-1.9%, respectively, in human embryonic retinoblasts. Degeneracy of the genetic code was used to engineer a codon-exchanged mRNA (cmRNA) that demonstrated complete resistance to silencing by the shRNA. Simulation of autosomal dominant retinitis pigmentosa in cell culture through triple transfection of DNAs expressing a cmRNA, a P23H mRNA and an shRNA revealed shRNA-mediated silencing, specifically of P23H rhodopsin by 90.64+/-5.19% and no loss of rhodopsin translation from the cmRNA in those cells. In addition, we present data on two alternative shRNA sequences targeting human rhodopsin. Our results have implications for the treatment of a very large variety of retinal degenerations in a mutation-independent manner.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15877050     DOI: 10.1038/sj.gt.3302512

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  24 in total

1.  Artificial mirtron-mediated gene knockdown: functional DMPK silencing in mammalian cells.

Authors:  Yiqi Seow; Christopher R Sibley; Matthew J A Wood
Journal:  RNA       Date:  2012-05-30       Impact factor: 4.942

2.  Long-term rescue of retinal structure and function by rhodopsin RNA replacement with a single adeno-associated viral vector in P23H RHO transgenic mice.

Authors:  Haoyu Mao; Marina S Gorbatyuk; Brian Rossmiller; William W Hauswirth; Alfred S Lewin
Journal:  Hum Gene Ther       Date:  2012-03-28       Impact factor: 5.695

Review 3.  Bottlenecks in development of retinal therapeutic post-transcriptional gene silencing agents.

Authors:  Jack M Sullivan; Edwin H Yau; R Thomas Taggart; Mark C Butler; Tiffany A Kolniak
Journal:  Vision Res       Date:  2007-10-31       Impact factor: 1.886

Review 4.  Nanoparticle applications in ocular gene therapy.

Authors:  Xue Cai; Shannon Conley; Muna Naash
Journal:  Vision Res       Date:  2007-09-06       Impact factor: 1.886

5.  In vitro analysis of ribozyme-mediated knockdown of an ADRP associated rhodopsin mutation.

Authors:  Dibyendu Chakraborty; Patrick Whalen; Alfred S Lewin; Muna I Naash
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

6.  Improved retinal function in a mouse model of dominant retinitis pigmentosa following AAV-delivered gene therapy.

Authors:  Naomi Chadderton; Sophia Millington-Ward; Arpad Palfi; Mary O'Reilly; Gearóid Tuohy; Marian M Humphries; Tiansen Li; Peter Humphries; Paul F Kenna; G Jane Farrar
Journal:  Mol Ther       Date:  2009-01-27       Impact factor: 11.454

Review 7.  Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy.

Authors:  A Guzman-Aranguez; P Loma; J Pintor
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

8.  Engineered zinc finger nuclease-mediated homologous recombination of the human rhodopsin gene.

Authors:  David L Greenwald; Siobhan M Cashman; Rajendra Kumar-Singh
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-07-29       Impact factor: 4.799

9.  Mutation-independent rescue of a novel mouse model of Retinitis Pigmentosa.

Authors:  D L Greenwald; S M Cashman; R Kumar-Singh
Journal:  Gene Ther       Date:  2012-07-19       Impact factor: 5.250

10.  A cellular high-throughput screening approach for therapeutic trans-cleaving ribozymes and RNAi against arbitrary mRNA disease targets.

Authors:  Edwin H Yau; Mark C Butler; Jack M Sullivan
Journal:  Exp Eye Res       Date:  2016-05-25       Impact factor: 3.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.